CA3171267A1 - A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof - Google Patents

A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof Download PDF

Info

Publication number
CA3171267A1
CA3171267A1 CA3171267A CA3171267A CA3171267A1 CA 3171267 A1 CA3171267 A1 CA 3171267A1 CA 3171267 A CA3171267 A CA 3171267A CA 3171267 A CA3171267 A CA 3171267A CA 3171267 A1 CA3171267 A1 CA 3171267A1
Authority
CA
Canada
Prior art keywords
subject
bcma
nirogacestat
dihydrobromide
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171267A
Other languages
English (en)
French (fr)
Inventor
Todd Webster SHEARER
Badreddin EDRIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SpringWorks Therapeutics Inc
Original Assignee
SpringWorks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpringWorks Therapeutics Inc filed Critical SpringWorks Therapeutics Inc
Publication of CA3171267A1 publication Critical patent/CA3171267A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
CA3171267A 2020-03-13 2021-03-12 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof Pending CA3171267A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989372P 2020-03-13 2020-03-13
US62/989,372 2020-03-13
PCT/US2021/022177 WO2021183934A1 (en) 2020-03-13 2021-03-12 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof

Publications (1)

Publication Number Publication Date
CA3171267A1 true CA3171267A1 (en) 2021-09-16

Family

ID=75396879

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171267A Pending CA3171267A1 (en) 2020-03-13 2021-03-12 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof

Country Status (17)

Country Link
US (1) US20230121547A1 (enExample)
EP (1) EP4132515A1 (enExample)
JP (2) JP7781764B2 (enExample)
KR (1) KR20230009873A (enExample)
CN (1) CN115916188A (enExample)
AR (1) AR121566A1 (enExample)
AU (1) AU2021236340A1 (enExample)
BR (1) BR112022018251A2 (enExample)
CA (1) CA3171267A1 (enExample)
CL (1) CL2022002479A1 (enExample)
CO (1) CO2022014388A2 (enExample)
IL (1) IL296075A (enExample)
MX (1) MX2022011258A (enExample)
PE (1) PE20230614A1 (enExample)
TW (1) TW202200132A (enExample)
WO (1) WO2021183934A1 (enExample)
ZA (1) ZA202209989B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240056726A (ko) 2021-09-01 2024-04-30 스프링웍스 테라퓨틱스, 인크. 니로가세스타트의 합성
WO2023064872A1 (en) * 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
CN118338900A (zh) * 2021-11-05 2024-07-12 斯普林渥克斯治疗有限公司 含尼罗加司他的组合物和治疗
AU2022396239A1 (en) * 2021-11-23 2024-06-06 Assia Chemical Industries Ltd. Solid state forms of nirogacestat salts
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
PE20250395A1 (es) 2022-05-20 2025-02-11 Springworks Therapeutics Inc Tratamientos con nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
CN120813574A (zh) * 2023-03-09 2025-10-17 苏州科睿思制药有限公司 尼罗司他二氢溴酸盐的晶型及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149855B2 (en) * 2014-02-05 2018-12-11 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides
HK1255694A1 (zh) * 2015-07-24 2019-08-23 Oncotracker, Inc. 用於治疗免疫系统功能障碍的γ分泌酶调节剂
WO2018151836A1 (en) * 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615055A1 (en) * 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) * 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
JP7050813B2 (ja) 2017-05-05 2022-04-08 華為技術有限公司 支援データ送信方法、デバイス、およびシステム
MX2020004568A (es) * 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
WO2019094626A1 (en) * 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies
TWI753229B (zh) * 2018-01-17 2022-01-21 美商明塞特製藥公司 用於治療癌症之組合療法
KR20210013184A (ko) * 2018-05-24 2021-02-03 아얄라 파마큐티컬즈 아이엔씨. 비스플루오로알킬-1,4-벤조디아제피논 화합물과 면역요법제를 포함하는 조성물 및 이의 사용 방법
EP3802611A2 (en) * 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
US20220168417A1 (en) * 2019-04-10 2022-06-02 Glaxosmithkline Intellectual Property Development Limited Combination therapy with an anti bcma antibody and a gamma secretase inhibitor
WO2021029854A1 (en) * 2019-08-09 2021-02-18 Pfizer Inc. Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Also Published As

Publication number Publication date
JP2023517243A (ja) 2023-04-24
CL2022002479A1 (es) 2023-08-18
BR112022018251A2 (pt) 2022-11-08
WO2021183934A1 (en) 2021-09-16
KR20230009873A (ko) 2023-01-17
AU2021236340A1 (en) 2022-09-29
JP7781764B2 (ja) 2025-12-08
PE20230614A1 (es) 2023-04-14
US20230121547A1 (en) 2023-04-20
IL296075A (en) 2022-11-01
CO2022014388A2 (es) 2023-02-16
JP2025168430A (ja) 2025-11-07
EP4132515A1 (en) 2023-02-15
AR121566A1 (es) 2022-06-15
TW202200132A (zh) 2022-01-01
CN115916188A (zh) 2023-04-04
ZA202209989B (en) 2025-12-17
MX2022011258A (es) 2023-01-11

Similar Documents

Publication Publication Date Title
US20230121547A1 (en) A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof
AU2022202686B2 (en) Methods of treating and preventing graft versus host disease
CN109562106B (zh) Cxcr4抑制剂及其用途
BR112012020142A2 (pt) moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos.
WO2023049831A1 (en) Treatment of human papillomavirus-associated cancers by pd-l1 inhibitors
UA119767C2 (uk) Лікування b-клітинних злоякісних новоутворень із застосуванням комбінації інгібіторів jak та pi3k
SG191744A1 (en) Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
KR20240019391A (ko) 혈액 장애를 치료하기 위한 화합물 및 조성물
JPH0586378B2 (enExample)
MX2007001054A (es) Imidazo[4,5-d]pirimidinas, sus usos y metodos de preparacion.
JP2023515888A (ja) ｅＩＦ４Ｅ阻害剤及びその使用
US11872220B2 (en) Methods and compositions for treating B-cell malignancies
WO2019241644A1 (en) Novel small molecule anticancer agents, combinations and uses thereof
WO2024254227A1 (en) Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
CN115317493A (zh) 一种硼酸类小分子化合物在制备增强免疫检查点抑制剂疗效及治疗白血病药物中的应用
TW202304436A (zh) 藥物組合及其應用
WO2021143792A1 (zh) 哌啶类化合物及其制备方法和医药用途
CN114206869A (zh) Cxcr4抑制剂和其用途
CN119074708A (zh) 氟他胺治疗头颈鳞癌的应用及其减毒增效组合物
EP4511371A1 (en) Substituted phenyl oxazolone compounds
WO2023091550A1 (en) Methods of treating estrogen receptor-associated diseases
Demidem et al. Sensitization of AIDS related non-Hodgkin's B lymphoma cell lines to cytotoxic drugs toxins by interferon-gamma
JP2012082157A (ja) 新規な医薬品組成物
ZA200201649B (en) Fused pyrrolecarboxamides: GABA brain receptor ligands.